Preservation of Inner Ear Functions: Extending Glucocorticoid Therapy by Tissue-Protective α1-Antitrypsin
Source abstract
Abstract
Protecting tissues from excessive inflammation by glucocorticoids results in an effective blockade of inflammation; however, it does not instigate processes of inflammatory resolution or tissue repair. Moreover, glucocorticoids have side effects such as a susceptibility to infections. In otolaryngology—specifically, within the inner ear—surgical and non-surgical pathologies include cochlear implantation, stapes surgery, perilymph fistulas and Meniere’s disease. For these, steroids are indicated in order to prevent excessive inflammation that might lead to hearing and vestibular failure. Unless tissue homeostasis is restored, the compromised tissue is at risk of a functional loss. α1-Antitrypsin (AAT) is a circulating inflammation-modulating molecule that rises during the molecular signs of a tissue injury; it manipulates inflammation towards an inflammatory resolution and advances tissue repair. Lifelong infusions of AAT are currently indicated for genetic AAT deficiencies and are safe. In the present review, we discuss the advantages and downfalls of glucocorticoid treatments across several surgical inner ear injuries alongside evidence of the beneficial attributes of treatments with AAT. Collectively, the present knowledge places AAT treatments, wither independent or in combination with glucocorticoids, as adding focus on tissue repair in the context of unmet medical needs in otolaryngology.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Vestibular and auditory disorders · Hearing, Cochlea, Tinnitus, Genetics · Ear Surgery and Otitis Media
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8443944, Israel
Department of Otolaryngology-Head & Neck Surgery, Soroka University Medical Center, Beer-Sheva 8410101, Israel
Funding
The Israel Science Foundation
References (91)
Show source-provided references
1. Immune-mediated hearing loss: Basic mechanisms and options for therapy10.1080/00016480260094965 ↗
2. Allergic and immunologic aspects of Meniere’s disease10.1016/S0194-59989670204-8 ↗
3. Molecular mechanism of autoimmune hearing loss10.1080/00016480260094893 ↗
4. Corticosteroid pharmacokinetics in the inner ear fluids: An animal study followed by clinical application10.1097/00005537-199907001-00001 ↗
5. Chemical perfusion of the inner ear10.1016/S0030-6665(02)00023-3 ↗
6. A Comprehensive Review of the Adverse Effects of Systemic Corticosteroid10.1016/j.otc.2010.04.003 ↗
7. Effects of steroids on wound healing: A review of the literature
8. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors10.1182/blood-2002-05-1496 ↗
9. Effects of cortisone acetate, methylprednisolone and medroxyprogesterone on wound contracture and epithelialization rabbits10.1097/00006534-197510000-00070 ↗
10. Acute phase protein α1-antitrypsin reduces the bacterial burden in mice by selective modulation of innate cell responses10.1093/infdis/jiu620 ↗
11. Acute-phase protein α1-anti-trypsin: Diverting injurious innate and adaptive immune responses from non-authentic threats10.1111/cei.12476 ↗
12. Differential signaling patterns of stimulated bone marrow-derived dendritic cells under α1-antitrypsin-enriched conditions10.1016/j.cellimm.2020.104281 ↗
13. Expanding the Clinical Indications for α1-Antitrypsin Therapy10.2119/molmed.2011.00196 ↗
14. Alpha-1 Antitrypsin Substitution for Extrapulmonary Conditions in Alpha-1 Antitrypsin Deficient Patients
15. Effects of prolastin C (plasma-derived alpha-1 antitrypsin) on the acute inflammatory response in patients with ST-segment elevation myocardial infarction (from the VCU-alpha 1-RT pilot study)10.1016/j.amjcard.2014.09.043 ↗
16. A1-antitrypsin therapy for non-deficient individuals: Integrating and mitigating cross-pathology inflammatory and immune responses to the injured cell
17. Effects of dietary restriction and antioxidants on presbyacusis10.1097/00005537-200005000-00003 ↗
18. Intravenous infusion of recombinant tissue plasminogen activator for the treatment of patients with sudden and/or chronic hearing loss10.1177/000348940311200802 ↗
19. Neurotrophins can enhance spiral ganglion cell survival after inner hair cell loss10.1016/S0736-5748(96)00117-7 ↗
20. Development of in vivo gene therapy for hearing disorders: Introduction of adeno-associated virus into the cochlea of the guinea pig
21. Restraint stress and protection from acoustic injury in mice10.1016/S0378-5955(02)00289-7 ↗
22. Sudden sensorineural hearing loss: Does application of glucocorticoids make sense?10.1001/archotol.127.3.253 ↗
23. Intratympanic dexamethasone for sudden sensorineural hearing loss: Clinical and laboratory evaluation10.1097/00129492-200101000-00005 ↗
24. Intratympanic steroids: Do they acutely improve hearing in cases of cochlear hydrops?10.1097/00005537-200311000-00008 ↗
25. Histopathology of the inner ear relevant to cochlear implantation
26. Surgical aspects of cochlear implantation: Mechanisms of insertional trauma
27. D-JNKI-1 treatment prevents the progression of hearing loss in a model of cochlear implantation trauma10.1097/00129492-200606000-00012 ↗
28. Blocking pro-cell-death signal pathways to conserve hearing10.1159/000241895 ↗
29. Dexamethasone protects auditory hair cells against TNFalpha-initiated apoptosis via activation of PI3K/Akt and NFkappaB signaling10.1016/j.heares.2009.05.003 ↗
30. Dexamethasone treatment of tumor necrosis factor-alpha challenged organ of Corti explants activates nuclear factor kappa B signaling that induces changes in gene expression that favor hair cell survival10.1016/j.neuroscience.2011.04.061 ↗
31. Conservation of hearing and protection of auditory hair cells against trauma-induced losses by local dexamethasone therapy: Molecular and genetic mechanisms10.1179/146701010X12671178390834 ↗
32. Drug delivery in cochlear implantation10.1080/00016489.2021.1888505 ↗
33. A retrospective analysis of the contribution of reported factors in cochlear implantation on hearing preservation outcomes10.1097/MAO.0000000000000753 ↗
34. Outcomes review of modern hearing preservation technique in cochlear implant10.1016/j.anl.2016.02.014 ↗
35. Preservation of hearing following cochlear implantation using different steroid therapy regimens: A prospective clinical study10.12659/MSM.906210 ↗
36. Systemic methylprednisolone for hearing preservation during cochlear implant surgery: A double blinded placebo-controlled trial10.1016/j.heares.2021.108224 ↗
37. Improving clinical outcomes in cochlear implantation using glucocorticoid therapy: A review10.1097/AUD.0000000000000740 ↗
38. The role of preoperative, intratympanic glucocorticoids for hearing preservation in cochlear implantation: A prospective clinical study10.1002/lary.22142 ↗
39. Hearing preservation using topical dexamethasone alone and associated with hyaluronic acid in cochlear implantation10.3109/00016489.2014.995831 ↗
40. Methylprednisolone applied directly to the round window reduces dizziness after cochlear implantation: A randomized clinical trial10.1159/000322137 ↗
41. The long-term effects of modified electrode surfaces and intracochlear corticosteroids on postoperative impedances in cochlear implant patients10.1097/MAO.0b013e3181ab8fba ↗
42. Intracochlear administration of steroids with a catheter during human cochlear implantation: A safety and feasibility study10.1007/s13346-018-0539-z ↗
43. Impact of perioperative oral steroid use on low-frequency hearing preservation after cochlear implantation10.1097/MAO.0000000000000847 ↗
44. The role of preoperative steroids for hearing preservation cochlear implantation: Results of a randomized controlled trial10.1159/000485310 ↗
45. Electrode array-eluted dexamethasone protects against electrode insertion trauma induced hearing and hair cell losses, damage to neural elements, increases in impedance and fibrosis: A dose response study10.1016/j.heares.2016.02.003 ↗
46. Wilk, M., Hessler, R., Mugridge, K., Jolly, C., Fehr, M., Lenarz, T., and Scheper, V. (2016). Impedance changes and fibrous tissue growth after cochlear implantation are correlated and can be reduced using a dexamethasone eluting electrode. PLoS ONE, 11.10.1371/journal.pone.0147552 ↗
47. Complications in stapes surgery. Options for prevention and management10.1016/S0030-6665(20)30822-7 ↗
48. Virial theorem and dynamical evolution of self-gravitating Brownian particles in an unbounded domain10.1103/PhysRevE.73.066103 ↗
49. Reparative granuloma following stapedectomy: A clinical entity10.1177/000348946707600511 ↗
50. New concepts in management of otospongiosis10.1001/archotol.1974.00780040433003 ↗
51. Etiology and therapy of cochlear drops following stapedectomy
52. Minimizing cochlear loss during and after stapedectomy10.1016/S0030-6665(20)32119-8 ↗
53. Management of the open labyrinth10.1016/S0194-59989570275-X ↗
54. Perioperative glucocorticoid treatment does not influence early post-laser stapedotomy hearing thresholds
55. Diagnosis and treatment of perilymphatic fistula
56. Perilymph fistula—45 case analysis10.1016/S0385-8146(00)00089-4 ↗
57. Delayed facial palsy after tympanomastoid surgery
58. Delayed post-stapedectomy facial paralysis: A report of five cases10.1288/00005537-197308000-00007 ↗
59. Oxygen toxicity and reactive oxygen species: The devil is in the details10.1203/PDR.0b013e3181a9eafb ↗
60. Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
61. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: A new hypothesis with supporting data10.1378/chest.118.5.1480 ↗
62. Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages10.1080/00365540701225744 ↗
63. Alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients10.1183/09031936.00047306 ↗
64. Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection10.1164/ajrccm.160.4.9807166 ↗
65. Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells10.3389/fpubh.2013.00019 ↗
66. S-nitrosylation of α1-antitrypsin triggers macrophages toward inflammatory phenotype and enhances intra-cellular bacteria elimination10.3389/fimmu.2019.00590 ↗
67. α1 Antitrypsin therapy modulates the neutrophil membrane proteome and secretome10.1183/13993003.01678-2019 ↗
68. In vitro and in vivo modulation of NADPH oxidase activity and reactive oxygen species production in human neutrophils by α1-antitrypsin10.1183/23120541.00234-2021 ↗
69. Trauma-induced vestibular dysfunction: Possible functional repair under α1-antitrypsin-rich conditions
70. Gimmon, A., Sherker, L., Kojukarov, L., Zaknoun, M., Lior, Y., Fadel, T., Schuster, R., Lewis, E.C., and Silberstein, E. (2022). Accelerated wound border closure using a microemulsion containing non-inhibitory recombinant α1-antitrypsin. Int. J. Mol. Sci., 23.10.3390/ijms23137364 ↗
71. Revascularization of pancreatic islet allografts is enhanced by α-1-antitrypsin under anti-inflammatory conditions10.3727/096368912X657701 ↗
72. Enhanced Survival and Accelerated Perfusion of Skin Flap to Recipient Site Following Administration of Human α1-Antitrypsin in Murine Models10.1089/wound.2018.0889 ↗
73. Protein-losing enteropathy as precursor of inflammatory bowel disease: A review of the literature10.1136/bcr-2020-238802 ↗
74. Clinical practice10.1007/s00431-010-1235-2 ↗
75. Therapeutic options for steroid-refractory acute and chronic GVHD: An evolving landscape10.1080/17474086.2020.1752175 ↗
76. Human-derived α1-antitrypsin is still efficacious in heavily pretreated patients with steroid-resistant gastrointestinal graft-versus-host disease10.1016/j.bbmt.2020.05.014 ↗
77. Endogenous α1-antitrypsin levels in the perilymphatic fluid correlates with severity of hearing loss10.1111/coa.13541 ↗
78. Enzymatic concept of otospongiosis and cochlear otospongiosis10.1111/j.1365-2273.1977.tb01331.x ↗
79. Distinct anti-inflammatory properties of alpha1-antitrypsin and corticosteroids reveal unique underlying mechanisms of action10.1016/j.cellimm.2020.104177 ↗
80. Antiinflammatory properties of hepatic acute phase proteins: Preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells10.1084/jem.178.5.1629 ↗
81. A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils10.1210/jcem-71-1-34 ↗
82. Bai, A., Feng, Z., Kadiyala, V., Aerts, S., Honda, J.R., and Li, L. (2019). Alpha-1-Antitrypsin Binds to Glucocorticoid Receptor to Induce Angiopoietin-Like Protein 4 Expression. C32 COPD: Translational and Mechanistic Studies, American Thoracic Society.
83. Cistrome-based Cooperation between Airway Epithelial Glucocorticoid Receptor and NF-kappaB Orchestrates Anti-inflammatory Effects10.1074/jbc.M116.721217 ↗
84. Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients10.1186/s13063-020-04522-9 ↗
85. A Preclinical Translational Study of the Cardioprotective Effects of Plasma-Derived Alpha-1 Anti-trypsin in Acute Myocardial Infarction10.1097/FJC.0000000000000474 ↗
86. Ceruletide and alpha-1 antitrypsin as a novel combination therapy for ischemic stroke10.1007/s13311-022-01203-0 ↗
87. Protective Effect of Alpha 1-Antitrypsin on Renal Ischemia-Reperfusion Injury10.1016/j.transproceed.2019.04.084 ↗
88. Protease inhibitors alpha1-antitrypsin and ilomastat are not ototoxic in the chinchilla10.1097/00005537-200310000-00019 ↗
89. Alpha1-antitrypsin single dose adjuvant therapy for acute otitis media10.1016/j.otohns.2005.11.050 ↗
90. Alpha 1-antitrypsin and ilomastat inhibit inflammatory proteases present in human middle ear effusions10.1097/00005537-200308000-00015 ↗
91. Recent advancements in bioelectronic devices to interface with the peripheral vestibular system10.1016/j.bios.2022.114521 ↗